Research scores advance in manipulating T-cells

October 11, 2012
Tew and colleagues have found a way not only to get inside naïve T cells, but to deliver bio-active cargo such as proteins and synthetic molecules across that long-locked cell membrane, by using a new synthetic protein transduction domain that mimics natural ones. Credit: UMass Amherst

(Medical Xpress)—Until recently, medical researchers had little hope of experimentally manipulating naïve T cells to study their crucial roles in immune function, because they were largely impenetrable, says polymer scientist Gregory Tew: "So far off limits we could not readily get inside to investigate their workings."

Now, he and colleagues including immunologist Lisa Minter have found a way not only to get inside naïve T , but to deliver bio-active cargo such as proteins and across that long-locked , by using a new synthetic protein transduction domain (PTD) that mimics natural ones. Tew and colleagues call their new macromolecules "PTD mimics" (PTDMs). They are able to slip through the T cell's membrane and deliver a payload of therapeutic (siRNA).

The invention is "something like a master key, because we can get into cells without their permission, and into difficult-to-access cell types like human T cells," says Tew. "We think it will lead to new advances in fundamental immunology and it also holds great potential for therapeutic applications in the clinic. We hope every on the planet hears about this delivery breakthrough, because now they can begin to study T cell function in new ways."

Earlier methods required electroporation or the use of viruses, which either decrease or pose unacceptable risks to patients in a treatment setting, he adds. Tew and Minter's work appears in the current issue of Molecular Therapy.

are a subset of that play a critical role in cell-mediated immunity, fighting against invading infections, cancer and HIV, for example. There are several different types of T cells, so named because they mature in the thymus gland. For years, scientists have wanted to study naïve T cells in particular, those that can respond to pathogens the immune system has not yet seen.

Tew, Minter and colleagues saw an unmet need for non-viral, efficient and easily prepared reagents for use in delivering siRNA into difficult-to-enter cell types such as human T cells. Successfully delivering siRNA into naïve would demonstrate efficient gene knockdown without toxicity and provide a powerful new immunologic tool.

The UMass Amherst team leaders say one of the things they tried to pioneer is being inspired by what nature does, then building synthetic mimics of that. "We felt that if we were not limited to the usual amino acid alphabet of proteins, we could do it better. That turned out to be true; we used biomimetic design principles to make PTDMs that are less toxic and more effective for moving cargo across the cell membrane than natural ones."

"What we modify is the chemical structure," Tew explains. "We've built the principles of a natural PTD into a new macromolecule that's bigger, longer, has more dense groups and different architecture. It slips into the T cell without damaging it, and can carry cargo, in this case siRNA, across that membrane."

They accomplished this by first identifying key features of natural PTDs, then capturing some of their chemical properties in new macromolecular synthetic polymer mimics. Specifically, they designed and studied two different PTDMs inspired by polyarginines and amphiphilic (able to cross both water and lipid membranes) peptides to deliver siRNA into two hard-to-transfect cell types: Cells from a line of immortalized human T lymphocytes and human peripheral blood cells from three different donors.

As one of several tests of effectiveness, they targeted knockdown of NOTCH1, a gene-controlling transmembrane receptor that also plays a role in T cell development, proliferation and differentiation. The authors report achieving 50 percent knockdown of NOTCH1 protein expression in both for up to 72 hours after one treatment.

"The T cell goes about its business. It looks normal except that it has much less NOTCH1," says Tew. "With this new tool, we expect we can fine-tune T cell activation. In the case of cancer surveillance, you may want to turn it up to stimulate immune responses, but with autoimmune diseases it would be beneficial to turn it down."

Explore further: New Synthetic Compound Message to Drug-Resistant Bacteria: 'Resistance is Futile'

Related Stories

DNA nanoparticles to carry drugs and gene therapy

April 22, 2011

(PhysOrg.com) -- DNA isn't just for genetics anymore. Cornell researchers are using synthetic DNA to make nanoparticles, dubbed DNAsomes, that can deliver drugs and genetic therapy to the insides of cells.

New memory for HIV patients

March 26, 2012

The hallmark loss of helper CD4+ T cells during human immunodeficiency virus (HIV) infection may be a red herring for therapeutics, according to a study published on March 26th in the Journal of Experimental Medicine.

Recommended for you

Basic research fuels advanced discovery

August 26, 2016

Clinical trials and translational medicine have certainly given people hope and rapid pathways to cures for some of mankind's most troublesome diseases, but now is not the time to overlook the power of basic research, says ...

New method creates endless supply of kidney precursor cells

August 25, 2016

Salk Institute scientists have discovered the holy grail of endless youthfulness—at least when it comes to one type of human kidney precursor cell. Previous attempts to maintain cultures of the so-called nephron progenitor ...

New avenue for understanding cause of common diseases

August 25, 2016

A ground-breaking Auckland study could lead to discoveries about many common diseases such as diabetes, cancer and dementia. The new finding could also illuminate the broader role of the enigmatic mitochondria in human development.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.